E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers A > Headlines for Achillion Pharmaceuticals, Inc. > News item
Published on 9/4/2008 in the Prospect News Special Situations Daily.

Xmark reports 3.6% stake in Achillion Pharmaceuticals

By Lisa Kerner

Charlotte, N.C., Sept. 4 - Xmark Opportunity Partners, LLC reported the purchase of 87,876 shares of Achillion Pharmaceuticals, Inc. between July 23 and Aug. 21.

The shares were priced from $2.49 to $3.00 each, according to a schedule 13D/A filed with the Securities and Exchange Commission.

Xmark beneficially owns 961,944 shares, or 3.6%, of the New Haven, Conn., biopharmaceutical company.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.